🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Affiliated Cancer Hospital & Institute of Guangzhou Medical University clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Affiliated Cancer Hospital & Institute of Guangzhou Medical University as lead sponsor. Synced 26 Sep 2026
5Current trials
4Recruiting now
5Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Affiliated Cancer Hospital & Institute of Guangzhou Medical University is the lead sponsor of 5 current clinical trials in our China register. 4 are recruiting patients now. The most common phase is Phase 2. The drugs named most often in its trials are Cisplatin, Iparomlimab and Tuvonralimab and Nedaplatin. The most-studied condition is Nasopharyngeal Carcinoma.

ClinicalTrials.gov trials by status

  • Recruiting480%
  • Active, closed120%

Trials by phase

  • Phase 2360%
  • Phase 3120%
  • Observational120%
01

Clinical trials sponsored by Affiliated Cancer Hospital & Institute of Guangzhou Medical University

5 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Nedaplatin Versus Cisplatin in Treatment for Nasopharyngeal Carcinoma
NCT04437329 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma
Phase 3 Recruiting 2020-08 China
QL1706 Combined With Chemotherapy and Anlotinib for the Treatment of Recurrent Ovarian Cancer
NCT07286240 · ClinicalTrials.gov ↗ · Treatment of Recurrent Ovarian Cancer
Phase 2 Recruiting 2025-11 China
QL1706 Plus Chemotherapy as Neoadjuvant Therapy for Locally Advanced Cervical Cancer: A Phase II Trial
NCT07286253 · ClinicalTrials.gov ↗ · Neoadjuvant Treatment for Locally Advanced Cervical Cancer
Phase 2 Recruiting 2025-10 China
A Prospective Study on the Diagnosis of Malignant Tumors With 18F-FGIn PET/CT
NCT07602569 · ClinicalTrials.gov ↗ · Cancer (With or Without Metastasis)
Observational Recruiting 2025-10 China
Surufatinib or Surufatinib Combined With Vinorelbine for Non-Small Cell Lung Cancer
NCT04922658 · ClinicalTrials.gov ↗ · Advanced Non-Small Cell Lung Cancer
Phase 2 Active, closed 2020-06 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Affiliated Cancer Hospital & Institute of Guangzhou Medical University trials

5 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Affiliated Cancer Hospital & Institute of Guangzhou Medical University trials

5 conditions
Nasopharyngeal Carcinoma1Treatment of Recurrent Ovarian Cancer1Neoadjuvant Treatment for Locally Advanced Cervical Cancer1Advanced Non-Small Cell Lung Cancer1Cancer (With or Without Metastasis)1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China54

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Nasopharyngeal Carcinoma

SponsorTrials
Sun Yat-sen University56
Zhejiang Cancer Hospital4
XIANG YANQUN3
Jiangxi Provincial Cancer Hospital3
Zhongshan People's Hospital, Guangdong, China3
Ming-Yuan Chen3

Sponsors with the most current trials registered for this condition.

06

Questions about Affiliated Cancer Hospital & Institute of Guangzhou Medical University trials

How many clinical trials does Affiliated Cancer Hospital & Institute of Guangzhou Medical University sponsor?

Affiliated Cancer Hospital & Institute of Guangzhou Medical University is the lead sponsor of 5 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Affiliated Cancer Hospital & Institute of Guangzhou Medical University trials recruiting?

Yes. 4 of its 5 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Affiliated Cancer Hospital & Institute of Guangzhou Medical University testing?

Its current trials name 5 drugs and biologicals as interventions. The most frequent are Cisplatin (1), Iparomlimab and Tuvonralimab (1), Nedaplatin (1), Surufatinib (1) and Vinorelbine (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.